6/2/2010

Centocor Ortho Biotech acquired RespiVert, which specializes in small-molecule, inhaled drugs for pulmonary diseases, for an undisclosed amount. "The addition of RespiVert's expert scientific team and discovery platforms for inhaled medicines strengthens our capabilities and further builds our pipeline of novel oral and biologic therapies for serious pulmonary diseases," said an official at Centocor Research and Development.

Related Summaries